Annual Drug Patent Expirations for BYSTOLIC
Bystolic is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and one Paragraph IV challenge.
Drug patent litigation for BYSTOLIC.
This drug has twenty-seven patent family members in twenty-two countries.
The generic ingredient in BYSTOLIC is nebivolol hydrochloride. Three suppliers are listed for this compound. Additional details are available on the nebivolol hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
